Cardiology/Vascular Diseases | New Developments

Abbott Laboratories

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold

Lead Product(s): Everolimus

Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESPRIT BTK

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 03, 2020

Details:

This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully resorbable device to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling advanced stages of peripheral artery disease (PAD).

PharmAbcine

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Korea, Republic Of

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Pharm Abcine Executes of a Material Cooperative Research and Development Agreement with NIH to Evaluate Efficacy of P-403 to Treat SCLS

Lead Product(s): PMC-403

Therapeutic Area: Cardiology/Vascular Diseases Product Name: PMC-403

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: NIH

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement August 18, 2020

Details:

Under this agreement, Kirk M. Druey, M.D., and colleagues at the NIAID will investigate PMC-403 in preclinical models. PharmAbcine will discuss potential clinical development in collaboration with the NIH as the study progresses.

LivaNova

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020

Lead Product(s): Autonomic regulation therapy

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vitaria

Highest Development Status: Undisclosed Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 12, 2020

Details:

LivaNova will present a poster at the European Society of Cardiology (ESC) Congress 2020 on the potential for autonomic regulation therapy (ART) via vagus nerve stimulation to improve long-term cardiovascular function in patients with heart failure.

Sinomed

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Sinomed Completes Enrollment in PIONEER-III pivotal US & Japanese Trial of the BuMA Supreme Coronary DES

Lead Product(s): Sirolimus

Therapeutic Area: Cardiology/Vascular Diseases Product Name: BuMA Suprem

Highest Development Status: Undisclosed Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 08, 2020

Details:

SINOMED completed 1-year follow-up in the PIONEER-III trial evaluating the BuMA Supreme Drug-Eluting Coronary Stent (DES). BuMA Supreme is Sinomed's second-generation DES with eG Coating, biodegradable polymer and sirolimus drug.

Pluristyx

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement

Lead Product(s): ESI human embryonic stem cells

Therapeutic Area: Cardiology/Vascular Diseases Product Name: ESI hESC

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: AgeX Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 16, 2020

Details:

The agreement is a key step in AgeX’s licensing and collaboration strategy to facilitate industry and academic access to its hESC lines, its PureStem® cell derivation and manufacturing platform, and its UniverCyte™ immunotolerance technology.

Octapharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

South Africa

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Octapharma USA & BioMatrix Support Research Focused on COVID-19 & Myocardial Dysfunction

Lead Product(s): Immune globulin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Norton Heart & Vascular Institute in Louisvill

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration May 28, 2020

Details:

Octapharma USA is donating Octagam® 10% and cutaquig® 16.5%, the company’s intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG), for the study. BioMatrix will be donating patient education, including instruction in subcutaneous injection.

Horizon Discovery Group

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Horizon Discovery and Pharmahungary Report Positive Early-Stage Results for Novel Micro-RNA Therapeutic

Lead Product(s): miRNA-125b

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2020

Details:

The micro-RNA was identified as suitable for further development based on favorable pharmacokinetic results as well as pharmacodynamic data at the molecular level.

Secarna Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Lipigon Pharma buys LNAplus based antisense drug candidates from Secarna Pharma

Lead Product(s): Antisense oligonucleotide therapies

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Large molecule

Partner/Sponsor/Collaborator: Lipigon

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition March 23, 2020

Details:

Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.

Ncardia

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

BELGIUM Belgium

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of ...

Lead Product(s): Cardiomyocytes

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: BlueRock Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 21, 2020

Details:

Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.

Find

Find Novel Drugs for Cardiology/Vascular Diseases under Development

Undisclosed

Product Type

Companies

Abbott Laboratories

Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold

PharmAbcine

Pharm Abcine Executes of a Material Cooperative Research and Development Agreement with NIH to Evaluate Efficacy of P-403 to Treat SCLS

LivaNova

LivaNova to Present Autonomic Regulation Therapy Findings for Heart Failure During European Society of Cardiology Congress 2020

Sinomed

Sinomed Completes Enrollment in PIONEER-III pivotal US & Japanese Trial of the BuMA Supreme Coronary DES

Pluristyx

AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement

Octapharma

Octapharma USA & BioMatrix Support Research Focused on COVID-19 & Myocardial Dysfunction

Horizon Discovery Group

Horizon Discovery and Pharmahungary Report Positive Early-Stage Results for Novel Micro-RNA Therapeutic

Secarna Pharma

Lipigon Pharma buys LNAplus based antisense drug candidates from Secarna Pharma

Ncardia

Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of ...